Paula L Hoffman

Title: Paula L Hoffman: Innovator in Neuropharmacology

Introduction

Paula L Hoffman is a notable inventor based in Denver, Colorado. She has made significant contributions to the field of neuropharmacology, particularly in the development of compounds aimed at alleviating withdrawal syndromes and associated brain damage.

Latest Patents

Hoffman holds a patent for "Compounds, compositions and method suitable for amelioration of withdrawal syndromes and withdrawal-induced brain damage." This patent discloses a series of N-substituted-4-uredo-5,7-dihalo-2-carboxy quinoline compounds. These compounds exhibit properties as antagonists of voltage-sensitive sodium channels and as selective competitive antagonists at the strychnine-intensive glycine site of N-methyl-D-aspartate receptors. The compounds are designed to prevent or reduce the signs and symptoms of neurohyperexcitability, particularly in patients withdrawing from chronic use of dependence-inducing agents such as ethanol, barbiturates, and opiates. The unique actions of these compounds also help in reducing excitotoxic neurodegeneration and anxiety without the undesirable CNS depressant side effects of previously used agents.

Career Highlights

Hoffman is associated with Lohocla Research Corporation, where she continues her innovative work in neuropharmacology. Her research focuses on developing effective treatments for individuals suffering from substance dependency and withdrawal symptoms.

Collaborations

Hoffman has collaborated with notable colleagues, including Boris Tabakoff and Lawrence Snell, who have contributed to her research endeavors.

Conclusion

Paula L Hoffman is a pioneering inventor whose work in developing compounds for the treatment of withdrawal syndromes has the potential to significantly impact the field of neuropharmacology. Her contributions are vital in addressing the challenges faced by individuals dealing with substance dependency.